Mylan has launched the generic version of Novartis‘s Gleevec tablets, Imatinib Mesylate, in 100mg and 400mg versions in the US.

The launch follows after the company received the final approval from the US Food and Drug Administration (FDA) for the drug’s Abbreviated New Drug Application (ANDA).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The ANDA for Imatinib Mesylate tablets is a kinase inhibitor, and submitted for multiple indications, including for several blood cancers.

The drug has been indicated for treatments of newly diagnosed adult and paediatric patients with Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP), in blast crisis (BC), accelerated phase (AP) or in CP after failure of interferon-alpha therapy.

“For the 12 months ending 31 July, Imatinib Mesylate tablets had sales of approximately $1.7bn in the US.”

Additional indications among others include adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL), as well as adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test.

For the 12 months ending 31 July, Imatinib Mesylate tablets had sales of approximately $1.7bn in the US, according to QuintilesIMS.

About 227 ANDAs are currently pending FDA approval with 45 of them being potential first-to-file opportunities, representing $45.5bn in annual brand sales.

Mylan has an oncology portfolio of more than 40 products and is among the largest suppliers of cancer medicines by volume in the US.

In the US alone, one out of every 13 prescriptions filled is a Mylan brand-name or generic product.